Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC

Phase 2 Unknown 17 enrolled The First Affiliated Hospital with Nanjing Medical University

NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm，open-label study to evaluate the efficacy and safety of tislelizumab plus chemotherapy for conversion therapy of patients with locally nonresectable ESCC.

Timeline

Start: 2022-01-01
Primary completion: 2022-08-01
Completion: 2022-11-01

Publications

Xu T, Bai J, Zhao K, Chen X, Wang S, Zhu S, Sun C, Zhao C, Wang T, Zhu L, Hu M, Pang F, Zhang J, Wang W, Shu Y, Li F, Zhou Y. Induction Therapy of Tislelizumab Combined with Cisplatin and 5-Fluorouracil and Subsequent Conversion Surgery in Patients with Unresectable Advanced Esophageal Squamous Cell Carcinoma: A Phase 2, Single Center Study. Ann Surg Oncol. 2024 Dec;31(13):9321-9331. doi: 10.1245/s10434-024-16033-x. Epub 2024 Aug 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cisplatin	Other / unclassified	850 mg/m2	Intravenous
Subject	Tislelizumab	Monoclonal antibody	200 mg	Intravenous
Subject	fluorouracil	Small molecule	850 mg/m2	Intravenous

Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC

Summary

Timeline

Publications

Drugs

Indications